Table 4 Sensitivity and specificity of MA-LC of the earlier clinical trial
Performance measures | CI (95%) | |
|---|---|---|
Specificity | 81.7% | (76–86%) |
Sensitivity | 91.5% | (83–96%) |
Sensitivity per stage | ||
|---|---|---|
Stage | Number of subjects | Sensitivity |
I | 63 | 92.3% |
II | 19 | 89.5% |
Performance measures | CI (95%) | |
|---|---|---|
Specificity | 81.7% | (76–86%) |
Sensitivity | 91.5% | (83–96%) |
Sensitivity per stage | ||
|---|---|---|
Stage | Number of subjects | Sensitivity |
I | 63 | 92.3% |
II | 19 | 89.5% |